Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Rare Diseases × FANG vaccine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma, Ewing 1 Sarcoma 1 Rare Diseases 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neoplasms, Connective and Soft Tissue 1 Neoplasms, Connective Tissue 1 Neoplasms, Bone Tissue 1 Neoplasms by Histologic Type 1 Neoplasms 1

Interventions

Temozolomide 1 Plasma Exchange 1 Irinotecan 1 Infliximab 1 FANG vaccine 1 Collagenases 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03495921 2023-04-26

VITA

Gradalis, Inc.

Phase 3 Terminated

32 enrolled 13 charts

Neoplasms, Neoplasms by Histologic Type, Neoplasms, Connective Tissue, Sarcoma, Sarcoma, Ewing, Neoplasms, Connective and Soft Tissue, Neoplasms, Bone Tissue, Neuroectodermal Tumors, Primitive, Peripheral, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡